RET (M918T)

RET · Variant type: point · HGVS: p.M918T

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Pralsetinib	100.0%	0.0%	93.43
2	Tenalisib	99.8%	0.2%	97.98
3	Fedratinib	99.6%	0.4%	96.21
4	Entrectinib	99.5%	0.5%	93.69
5	Alpelisib	99.1%	0.9%	97.22
6	Selpercatinib	98.5%	1.5%	96.72
7	Alectinib	97.6%	2.4%	95.49
8	Gilteritinib	96.9%	3.1%	88.97
9	Tivozanib	96.6%	3.4%	92.42
10	Vandetanib	96.0%	4.0%	95.74
11	Nintedanib	95.5%	4.5%	90.23
12	Sunitinib	95.3%	4.7%	91.73
13	Sorafenib	94.5%	5.5%	96.72
14	Futibatinib	93.7%	6.3%	98.48
15	Ponatinib	93.1%	6.9%	78.23
16	Regorafenib	93.1%	6.9%	95.99
17	Lenvatinib	91.9%	8.1%	97.74
18	Erdafitinib	89.2%	10.8%	95.71
19	Avapritinib	88.9%	11.1%	97.73
20	Cabozantinib	82.4%	17.6%	92.73
21	Canertinib	79.9%	20.1%	96.49
22	Defactinib	77.6%	22.4%	92.68
23	Repotrectinib	77.0%	23.0%	84.21
24	Apatinib	75.3%	24.7%	97.73
25	Brigatinib	74.9%	25.1%	82.96

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Pralsetinib	100.0%	100.0%	+0.0%
Tenalisib	99.8%	98.5%	+1.3%
Fedratinib	99.6%	99.9%	-0.3%
Entrectinib	99.5%	99.6%	-0.0%
Alpelisib	99.1%	99.6%	-0.5%
Selpercatinib	98.5%	100.0%	-1.5%
Alectinib	97.6%	97.8%	-0.2%
Gilteritinib	96.9%	100.0%	-3.1%
Tivozanib	96.6%	99.7%	-3.1%
Vandetanib	96.0%	98.6%	-2.6%
Nintedanib	95.5%	100.0%	-4.5%
Sunitinib	95.3%	97.2%	-1.9%
Sorafenib	94.5%	94.0%	+0.6%
Futibatinib	93.7%	97.7%	-4.0%
Ponatinib	93.1%	100.0%	-6.9%
Regorafenib	93.1%	98.7%	-5.6%
Lenvatinib	91.9%	98.8%	-7.0%
Erdafitinib	89.2%	94.7%	-5.5%
Avapritinib	88.9%	—	—
Cabozantinib	82.4%	97.5%	-15.1%
Canertinib	79.9%	—	—
Defactinib	77.6%	—	—
Repotrectinib	77.0%	—	—
Apatinib	75.3%	—	—
Brigatinib	74.9%	94.9%	-20.0%

Cancer	Organ	Source
carcinoma_thyroid	Thyroid	ref
pheochromocytoma_adrenal_gland	Adrenal	ref
carcinoma_breast	Breast	ref
carcinoma_biliary_tract	Biliary Tract	ref
PCPG	Adrenal	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 16.2ms